We are live on ! Find out more
SBFM

Sunshine Biopharma

9 hedge funds and large institutions have $142K invested in Sunshine Biopharma in 2025 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0.26% less ownership

Funds ownership: 0.5%0.23% (-0.26%)

18% less funds holding

Funds holding: 119 (-2)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

58% less capital invested

Capital invested by funds: $337K → $142K (-$196K)

Holders
9
Holders Change
-2
Holders Change %
-18.18%
% of All Funds
0.11%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
2
Reduced
1
Closed
4
Calls
Puts
Net Calls
Net Calls Change

SBFM Hedge Fund Activity: Q4 2025 in Review

9 of the 8,257 institutional investors tracked by Wall St. Rank reported a position in Sunshine Biopharma (SBFM) for Q4 2025, worth a combined $142K — down 58% from $337K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of SBFM and 2 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.

The largest buyer was Virtu Financial, opening a new position worth an estimated $37K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $83K sold.

  • 9 institutional investors held Sunshine Biopharma (SBFM) as of Q4 2025, down from 11 in Q3 2025.
  • Funds reported $142K of Sunshine Biopharma stock for Q4 2025, down 58% quarter-over-quarter.
  • 2 funds opened new Sunshine Biopharma positions in Q4 2025 and 4 closed out, a net change of -2 holders.
  • The largest Sunshine Biopharma buyer in Q4 2025 was Virtu Financial, an estimated $37K added.
  • The largest Sunshine Biopharma seller in Q4 2025 was Renaissance Technologies, an estimated $83K sold.

Based on aggregated 13F filings for Q4 2025.